What does DELAPHARMA do?

DELAPHARMA is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 13 October 2004, 1 establishment.

What is the address of DELAPHARMA?

The registered office of DELAPHARMA is located at Grote Markt(D) 4, 8600 Diksmuide.

Is DELAPHARMA still active?

Yes. According to the CBE (16 September 2026) DELAPHARMA is active, legal situation “Normale toestand”, started on 13 October 2004.

Is DELAPHARMA registered on Peppol?

Yes, DELAPHARMA is registered on the Peppol network with ID 0208:0867801095.

What is the enterprise number of DELAPHARMA?

The enterprise number of DELAPHARMA is BE0867801095.

When was DELAPHARMA founded?

DELAPHARMA was founded on 13 October 2004.

Who are the directors of DELAPHARMA?

According to the 2025 annual accounts, the directors of DELAPHARMA are: Victor Delplancke.

Is DELAPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 October 2004; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DELAPHARMA make in 2025?

DELAPHARMA recorded a loss after taxes of € 93,278 in financial year 2025.

What is the revenue of DELAPHARMA?

As a small company, DELAPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 72,364.

DELAPHARMA (Private Limited) - Diksmuide - BE0867801095

Dossier DELAPHARMA, printed on 16 September 2026 from databakkes.be/en/0867801095/delapharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 5 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

DELAPHARMA from Diksmuide, company number BE0867801095, closed financial year 2025 with a result of € -93,278 after tax. For that financial year DELAPHARMA recorded a gross margin of € 72,364 and equity of € 1.3 million. Compared with financial year 2024, the result moved from € 341,359 to € -93,278. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 1, 2026.

What it is worth Healthy

€ 1.3 million

▼ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -93,278

▼ still € 341,359 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 76,136

▲ 143% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 1.2 million.

People and assets in 2025

Vehicles and equipment

€ 84,337

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 387,636

▼ 8% vs 2024

€ 32,181 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 15,272

▲ € 13,224 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 8,047

▼ 92% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 157,029 Gross margin 2022: € 157,029 First fiscal year in the series	€ 206,100 Gross margin 2023: € 206,100 ▲ 31% vs 2022 (€ 157,029) Favourable step	€ 160,537 Gross margin 2024: € 160,537 ▼ 22% vs 2023 (€ 206,100) Unfavourable step	€ 72,364 Gross margin 2025: € 72,364 ▼ 55% vs 2024 (€ 160,537) Unfavourable step	▼ 55%
Profit after taxes	€ 13,963 Profit after taxes 2022: € 13,963 First fiscal year in the series	€ 12,923 Profit after taxes 2023: € 12,923 ▼ 7% vs 2022 (€ 13,963) Unfavourable step	€ 341,359 Profit after taxes 2024: € 341,359 ▲ € 328,436 vs 2023 (€ 12,923) Favourable step	€ -93,278 Profit after taxes 2025: € -93,278 ▼ € 434,637 vs 2024 (€ 341,359) Unfavourable step	▼ € 434,637
Equity	€ 992,039 Equity 2022: € 992,039 First fiscal year in the series	€ 1,004,962 Equity 2023: € 1,004,962 ▲ 1% vs 2022 (€ 992,039) Favourable step	€ 1,346,321 Equity 2024: € 1,346,321 ▲ 34% vs 2023 (€ 1,004,962) Favourable step	€ 1,253,043 Equity 2025: € 1,253,043 ▼ 7% vs 2024 (€ 1,346,321) Unfavourable step	▼ 7%
Total debts	€ 1,124,746 Total debts 2022: € 1,124,746 First fiscal year in the series	€ 1,671,485 Total debts 2023: € 1,671,485 ▲ 49% vs 2022 (€ 1,124,746) Unfavourable step	€ 2,028,920 Total debts 2024: € 2,028,920 ▲ 21% vs 2023 (€ 1,671,485) Unfavourable step	€ 2,250,982 Total debts 2025: € 2,250,982 ▲ 11% vs 2024 (€ 2,028,920) Unfavourable step	▲ 11%
Cash	€ 284,489 Cash 2022: € 284,489 First fiscal year in the series	€ 172,311 Cash 2023: € 172,311 ▼ 39% vs 2022 (€ 284,489) Unfavourable step	€ 31,278 Cash 2024: € 31,278 ▼ 82% vs 2023 (€ 172,311) Unfavourable step	€ 76,136 Cash 2025: € 76,136 ▲ 143% vs 2024 (€ 31,278) Favourable step	▲ 143%
Land & buildings	€ 1,100,213 Land & buildings 2022: € 1,100,213 First fiscal year in the series	€ 1,756,163 Land & buildings 2023: € 1,756,163 ▲ 60% vs 2022 (€ 1,100,213) Unchanged	€ 2,582,591 Land & buildings 2024: € 2,582,591 ▲ 47% vs 2023 (€ 1,756,163) Unchanged	€ 2,604,494 Land & buildings 2025: € 2,604,494 ▲ 1% vs 2024 (€ 2,582,591) Unchanged	▲ 1%
Retained profit	€ 973,439 Retained profit 2022: € 973,439 First fiscal year in the series	€ 986,362 Retained profit 2023: € 986,362 ▲ 1% vs 2022 (€ 973,439) Favourable step	€ 1,327,721 Retained profit 2024: € 1,327,721 ▲ 35% vs 2023 (€ 986,362) Favourable step	€ 1,234,443 Retained profit 2025: € 1,234,443 ▼ 7% vs 2024 (€ 1,327,721) Unfavourable step	▼ 7%
Bank debt	€ 537,602 Bank debt 2022: € 537,602 First fiscal year in the series	€ 473,189 Bank debt 2023: € 473,189 ▼ 12% vs 2022 (€ 537,602) Favourable step	€ 419,503 Bank debt 2024: € 419,503 ▼ 11% vs 2023 (€ 473,189) Favourable step	€ 387,636 Bank debt 2025: € 387,636 ▼ 8% vs 2024 (€ 419,503) Favourable step	▼ 8%
Balance sheet total	€ 2,116,785 Balance sheet total 2022: € 2,116,785 First fiscal year in the series	€ 2,676,448 Balance sheet total 2023: € 2,676,448 ▲ 26% vs 2022 (€ 2,116,785) Unchanged	€ 3,375,241 Balance sheet total 2024: € 3,375,241 ▲ 26% vs 2023 (€ 2,676,448) Unchanged	€ 3,504,025 Balance sheet total 2025: € 3,504,025 ▲ 4% vs 2024 (€ 3,375,241) Unchanged	▲ 4%

Key figures of DELAPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to DELAPHARMA?

What happened at DELAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 1, 2026 New annual accounts for financial year 2025: loss of € 93,278 (▼ € 434,637 vs 2024). Source: NBB ↗
2009 Victor Delplancke became a director. NBB
Oct 13, 2004 New establishment in Diksmuide. KBO
Oct 13, 2004 Start of the company according to the CBE. KBO

In short

From € 13,963 profit in 2022 to € 93,278 loss in 2025.

Paid € 22,686 in corporate taxes since 2022.

Best year ever: 2024, with € 341,359 profit.

Original PDFs at the National Bank ↗

A new publication or filing at DELAPHARMA? We notify you, reason included.

Follow DELAPHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Victor Delplancke

DELAPHARMA

Apotheek Delplancke 100%

Behind DELAPHARMA is Victor Delplancke. It owns 100% of Apotheek Delplancke itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Victor Delplancke

Director

Also active at: APOTHEEK DELPLANCKE

since 2009

Establishments

Establishment units

Physical locations of this company

Registered office

Grote Markt(D) 4

8600 Diksmuide

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK DELPLANCKE same network

€ 243,415 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0867.801.095

VAT number

BE 0867.801.095

Registered office

Grote Markt(D) 4, 8600 Diksmuide

Names & denominations

DELAPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

13 October 2004

Peppol

Active · Active since 13 Jan 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

DELAPHARMA

Warning lights

Financials

What happened to DELAPHARMA?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions